Articles

Long-form pieces on what the published Retatrutide record actually contains. Every article closes with the primary sources it draws on.

• Retatrutide adds a third receptor. What the third one does is still mostly a mouse result.

  2026-09-20

  Approved incretin drugs act at one receptor or two. Retatrutide acts at three, and the third is the glucagon receptor. That extra target is the whole reason it gets described as a different class rather than a stronger version of what exists. But the claims made about it sit on very different kinds of evidence, and sorting them by what actually supports each one is more useful than any summary.

• Retatrutide has real trial data. That is not what people are buying.

  2026-09-16

  Retatrutide has completed late-stage trials with published results. It is also not approved anywhere, so the material people buy is not the material that was studied. When three products sold as retatrutide were tested, the amount in the vial ranged from about half the label to nearly double it.